84 related articles for article (PubMed ID: 34403984)
21. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
22. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
23. Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma.
Teran-Saavedra NG; Sarabia-Sainz JA; Silva-Campa E; Burgara-Estrella AJ; Guzmán-Partida AM; Ramos-Clamont Montfort G; Pedroza-Montero M; Vazquez-Moreno L
Molecules; 2019 Apr; 24(7):. PubMed ID: 30970533
[TBL] [Abstract][Full Text] [Related]
24. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
[TBL] [Abstract][Full Text] [Related]
25. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
[TBL] [Abstract][Full Text] [Related]
26. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
27. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
28. Ataxia telangiectasia mutated inhibitor-loaded copper sulfide nanoparticles for low-temperature photothermal therapy of hepatocellular carcinoma.
Cai H; Dai X; Guo X; Zhang L; Cao K; Yan F; Ji B; Liu Y
Acta Biomater; 2021 Jun; 127():276-286. PubMed ID: 33812073
[TBL] [Abstract][Full Text] [Related]
29. Bromelain-decorated hybrid nanoparticles based on lactobionic acid-conjugated chitosan for in vitro anti-tumor study.
Wei B; He L; Wang X; Yan GQ; Wang J; Tang R
J Biomater Appl; 2017 Aug; 32(2):206-218. PubMed ID: 28618976
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of the antiproliferative efficacy of BRM270 phytocomposite nanoparticles against human hepatoma cancer cell lines.
Gera M; Kim N; Ghosh M; Sharma N; Huynh DL; Chandimali N; Koh H; Zhang JJ; Kang TY; Park YH; Kwon T; Jeong DK
Mater Sci Eng C Mater Biol Appl; 2019 Apr; 97():166-176. PubMed ID: 30678901
[TBL] [Abstract][Full Text] [Related]
31. Berberine-loaded Janus nanocarriers for magnetic field-enhanced therapy against hepatocellular carcinoma.
Wang Z; Wang YS; Chang ZM; Li L; Zhang Y; Lu MM; Zheng X; Li M; Shao D; Li J; Chen L; Dong WF
Chem Biol Drug Des; 2017 Mar; 89(3):464-469. PubMed ID: 27618577
[TBL] [Abstract][Full Text] [Related]
32. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles.
Liu Q; Li R; Zhu Z; Qian X; Guan W; Yu L; Yang M; Jiang X; Liu B
Int J Pharm; 2012 Jul; 430(1-2):350-8. PubMed ID: 22525076
[TBL] [Abstract][Full Text] [Related]
33. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
34. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
Thao LQ; Lee C; Kim B; Lee S; Kim TH; Kim JO; Lee ES; Oh KT; Choi HG; Yoo SD; Youn YS
Colloids Surf B Biointerfaces; 2017 Apr; 152():183-191. PubMed ID: 28110040
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
37. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
[TBL] [Abstract][Full Text] [Related]
38. An organic solvent-free technology for the fabrication of albumin-based paclitaxel nanoparticles for effective cancer therapy.
Zhao Y; Cai C; Liu M; Zhao Y; Pei W; Chu X; Zhang H; Wang Z; Han J
Colloids Surf B Biointerfaces; 2019 Nov; 183():110394. PubMed ID: 31398618
[TBL] [Abstract][Full Text] [Related]
39. Bufalin-loaded bovine serum albumin nanoparticles demonstrated improved anti-tumor activity against hepatocellular carcinoma: preparation, characterization, pharmacokinetics and tissue distribution.
Zhang H; Huang N; Yang G; Lin Q; Su Y
Oncotarget; 2017 Sep; 8(38):63311-63323. PubMed ID: 28968991
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy.
Yu CY; Wang YM; Li NM; Liu GS; Yang S; Tang GT; He DX; Tan XW; Wei H
Mol Pharm; 2014 Feb; 11(2):638-44. PubMed ID: 24383625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
